Total current assets Total assets Total current liabilities Total liabilities Total stockholders’ equity Balance Balance Stockholders’ equity Total liabilities and stockholders’ equity Total operating expenses Loss from operations Total other income Net loss and comprehensive loss Net loss Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Cash used in operations Net cash used in investing activities Net cash provided by financing activities Net change in cash and cash equivalents Cash and cash equivalents – beginning of the period Cash and cash equivalents – end of the period Description of Business and Summary of Significant Accounting Policies [Abstract] Recent Accounting Pronouncements [Abstract] Fair Value Measurements [Abstract] Financial Assets [Abstract] Total financial assets Fair Value Hierarchy and NAV [Axis] Accrued Liabilities [Abstract] Schedule of Accrued Liabilities [Abstract] Total accrued liabilities Accrued liabilities Asset Purchase Agreement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Stockholders’ Equity [Abstract] Stockholders’ equity: Financial Instrument [Axis] Outstanding, Beginning Outstanding, Ending Equity-Based Compensation [Abstract] Statistical Measurement [Axis] Schedule of Activity Under the Plans [Abstract] Number Outstanding, Balance Weighted-Average Exercise Price Per Share, Balance Aggregate Intrinsic Value, Balance Net Loss Per Share [Abstract] Antidilutive Securities [Axis] Leases, Commitments, and Contingencies [Abstract] Schedule of Future Annual Lease Payments Under Non-Cancellable Operating Leases [Abstract] Total lease payments Subsequent Events [Abstract] Assets: Financial Assets: Current assets: Cash and cash equivalents Interest receivable Prepaid expenses and other current assets Deferred offering costs Property, plant and equipment, net Other assets Liabilities and Stockholders’ Equity: Current liabilities: Accounts payable Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 Preferred stock par value (in Dollars per share) Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Preferred stock, shares authorized Preferred stock, shares issued (in Shares) Preferred stock, shares outstanding (in Shares) Common stock, $0.001 par value; 75,000,000 shares authorized, 2,506,817 shares issued and outstanding as of March 31, 2026; 2,338,127 shares issued and outstanding as of December 31, 2025 Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, shares authorized Common stock, shares issued (in Shares) Common stock, shares outstanding (in Shares) Additional paid-in capital Accumulated deficit Operating expenses: General and administrative expenses Research and development expenses Depreciation expense Other income Interest and dividend income Net loss per common share, basic (in Dollars per share) Net loss per common share, basic Net loss per common share, diluted (in Dollars per share) Net loss per common share, diluted Weighted average number of common shares used in computing net loss per common share, basic (in Shares) Weighted average common shares outstanding Weighted average number of common shares used in computing net loss per common share, diluted (in Shares) Equity-based compensation - options Proceeds from sale of common stock under the ATM, net of issuance costs Proceeds from sale of common stock under the ATM, net of issuance costs (in Shares) Number of shares Proceeds from sale of common stock, net issuance costs Issuance of common stock for consulting services Issuance of common stock for consulting services (in Shares) Cash flows used in operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Equity-based compensation Changes in operating assets and liabilities: Accounts payable Accrued liabilities Cash flows used in investing activities: Cash flows from financing activities: Proceeds from sale of common stock under ATM Issuance costs for sale of common stock under ATM Interest receivable Prepaid expenses Deferred offering costs Investment in property and equipment Common Stock Common Stock [Member] Additional Paid-In Capital Accumulated Deficit Description of Business and Summary of Significant Accounting Policies Recent Accounting Pronouncements Fair Value Measurements Schedule of Financial Assets and Liabilities Subject to Fair Value Measurements Money market funds Accrued Liabilities Schedule of Accrued Liabilities Accrued compensation Accrued research and development Accrued professional fees Other Asset Purchase Agreement Schedule of Development Milestones Milestone payment Schedule of Initial Purchase Price of the Assets Acquired In process research and development Transaction costs Total Consideration asset Stockholders’ Equity Schedule of Total Warrants Outstanding Issue Date Exercise Price Per Share (in Dollars per share) Common warrant price per share (in Dollars per share) Exercise price Expiration Date New Issuance Equity-Based Compensation Schedule of Assumptions Used in Black-Scholes Model Risk-free interest rate Dividend yield Expected term (years) Volatility Schedule of Activity Under the Plans Weighted-Average Remaining Contractual Life (Years), Balance Number Outstanding, Granted Weighted-Average Exercise Price Per Share, Granted Options granted (in Dollars per share) Aggregate Intrinsic Value, Granted Weighted-Average Exercise Price Per Share, Exercised Aggregate Intrinsic Value, Exercised Weighted-Average Exercise Price Per Share, Canceled/forfeited/expired Aggregate Intrinsic Value, Canceled/forfeited/expired Number Outstanding, Options vested and exercisable Weighted-Average Exercise Price Per Share, Options vested and exercisable Weighted-Average Remaining Contractual Life (Years), Options vested and exercisable Aggregate Intrinsic Value, Options vested and exercisable Number Outstanding, Options vested and expected to vest Weighted-Average Exercise Price Per Share, Options vested and expected to vest Weighted-Average Remaining Contractual Life (Years), Options vested and expected to vest Aggregate Intrinsic Value, Options vested and expected to vest Schedule of Equity-Based Compensation Expense Total equity-based compensation expense Net Loss Per Share Schedule of Basic and Diluted Net Loss Per Common Share Numerator: Net loss Denominator: Schedule of Common Stock Equivalents were Excluded from the Calculation of Diluted Net Loss Per Share Anti-dilutive common stock equivalents: Total anti-dilutive common stock equivalents Leases, Commitments, and Contingencies Schedule of Future Annual Lease Payments Under Non-Cancellable Operating Leases 2026 Subsequent Events Exercised Number Outstanding, Exercised Number Outstanding, Canceled/forfeited/expired Level 1 [Member] Level 2 [Member] Level 3 [Member] First Patient Dosed in Phase 2 Initiated with Frunexian or EP-7327 [Member] First Patient Dosed in Phase 1 Initiated with EP-7327 [Member] First Patient Dosed in Phase 3 Initiated with Frunexian or EP-7327 [Member] FDA Approval of New Drug Application for Frunexian or EP-7327 [Member] First Patient Dosed in the First Clinical Trial with CAD-1005 [Member] First regulatory filing approval to market a pharmaceutical product for human use containing a Compound that is covered by a patent owned or licensed by Veralox (the “Product”) in the United States [Member] First regulatory filing approval to market a Product outside the United States [Member] Regulatory filing approval to market a Product for a subsequent indication in the United States [Member] Regulatory filing approval to market a Product for a subsequent indication outside the United States [Member] eXIthera APA [Member] Veralox APA [Member] Placement agent warrants [Member] Placement agent warrants [Member] Representative Warrants [Member] Placement agent warrants [Member] New Series A-1 warrants [Member] New Series A-2 warrants [Member] Placement agent warrants [Member] Investor Warrants 2025 [Member] Placement agent warrants [Member] Minimum [Member] Maximum [Member] Location, Statement of Income, Balance [Axis] Stock options to purchase common stock [Member] Warrants to purchase common stock [Member] Warrant [Member] Related Party Transaction [Axis] Sale of Stock [Axis] Product and Service [Axis] Class of Stock [Axis] Class of Warrant or Right [Axis] Plan Name [Axis] Subsequent Event Type [Axis] Non-cash expenses Net working capital Cash balances insured amount Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Operating segment Description of CODM Reportable segment Percentage of uncertain income tax position Consideration purchase of assets Annual net sales percentage Direct transaction costs License agreement amount Royalty revenue received Royalty expense Common stock vote held Sale and issuance of shares Share issued price (in Dollars per share) Gross proceeds from private placement (in Dollars) Expire term Sold shares Purchase warrant shares Total gross proceeds (in Dollars) Net proceeds (in Dollars) Net proceeds Maximum number of shares of common stock Calendar year Percentage of common stock outstanding Remained available for future issuance Common stock award shares Percentage of reserved shares of common stock available for issuance Remained shares available for future issuance Weighted average grant date fair value of options granted (in Dollars per share) Unrecognized stock-based compensation expense (in Dollars) Weighted average remaining requisite service period Lease term Operating lease expense Cash paid for office lease Purchase shares of common stock Term of warrants exercisable Aggregate gross proceeds Percentage of cash fee Percentage of exercise price of new warrants Stockholders equity requirement Basis of Presentation Liquidity Emerging Growth Company Status Use of Estimates Concentration of Credit and Other Risks and Uncertainties Segment Reporting Cash and Cash Equivalents Stock-Based Compensation Deferred Offering Costs Acquisitions Income Taxes Net Loss Per Common Share Comprehensive Loss Research and Development Expenses Patents eXIthera Pharmaceuticals, Inc. [Member] Asset Purchase Agreement [Member] Haisco Licensing Agreement [Member] Veralox Therapeutics Inc. [Member] Royalty [Member] 2025 Common Warrants [Member] Private Placement [Member] Series A-1 Warrants [Member] 2022 Plan [Member] Existing Warrants [Member] Subsequent Event [Member] Existing Warrant Shares [Member] Series B-1 Warrants [Member] New Warrants [Member] Series B-2 Warrants [Member] Warrant Inducement [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Measurements - Schedule of Financial Assets and Liabilities Subject to Fair Value Measurements (Details) [Table] Schedule of Financial Assets and Liabilities Subject to Fair Value Measurements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Asset Purchase Agreement - Schedule of Development Milestones (Details) [Table] Schedule of Contingent Milestone Payments [Line Items] Asset Acquisition [Table] Schedule of Initial Purchase Price of the Assets Acquired [Line Items] Financial Instruments [Domain] Class of Warrant or Right [Table] Schedule of Total Warrants Outstanding [Line Items] Statistical Measurement [Domain] Equity-Based Compensation - Schedule of Assumptions Used in Black-Scholes Model (Details) [Table] Schedule of Assumptions Used in Black-Scholes Model [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Equity-Based Compensation Expense [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Common Stock Equivalents were Excluded from the Calculation of Diluted Net Loss Per Share [Line Items] Sale of Stock [Domain] Related Party Transaction [Domain] Product and Service [Domain] Asset Purchase Agreement (Details) [Table] Asset Purchase Agreement [Line Items] Class of Stock [Domain] Class of Warrant or Right [Domain] Stockholders’ Equity (Details) [Table] Stockholders’ Equity [Line Items] Plan Name [Domain] Equity-Based Compensation (Details) [Table] Equity-Based Compensation [Line Items] Leases, Commitments, and Contingencies (Details) [Table] Leases, Commitments, and Contingencies [Line Items] Subsequent Event Type [Domain] Subsequent Events (Details) [Table] Subsequent Events [Line Items] Accrued research and development. Disclosure of accounting policy for acquisitions. Amount of transaction cost incurred in process research and development. Calendar year. Expiration Date. Issue Date. The percentage of common stock outstanding percentage. Disclosure of accounting policy for deferred offering costs. Disclosure of accounting policy emerging growth company status. The tabular disclosure of leases commitments and contingencies. Disclosure of accounting policy for liquidity. Maximum number of shares of common stock. Net proceeds. Disclosure of accounting policy for Patent. The amount represents payments of milestones. Percentage of cash fee. Percentage of exercise price of new warrants. Percentage of uncertain Income tax position. Purchase shares of common stock. Remained available shares for future issuance. Reserved shares of common Stock available for issuance. Amount of revenue received from royalty. Seller royalties percentage. The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. The amount of aggregate intrinsic value granted. The amount of aggregate intrinsic value canceled/forfeited/expired. Number of share options (or share units) exercised during the current period. Amount of minimum stockholders equity requirement. Term of warrants exercisable. Total gross proceeds. Represent the amount of workings capital. Chief Executive Officer Number of Operating Segments Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Use of Estimates, Policy [Policy Text Block] First Patient Dosed In The First Clinical Trial With CAD1005 Member Assets [Abstract] Comprehensive Income, Policy [Policy Text Block] Nonoperating Income (Expense) [Abstract] Proceeds from Issuance of Warrants Earnings Per Share, Diluted Retained Earnings [Member] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted Average Number of Shares Outstanding, Basic First Patient Dosed In Phase3 Initiated With Frunexian Or EP7327 Member Investor Warrants2025 Member Common Stock, Value, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Patent Policy Text Block Twenty Twenty Five Common Stock Member Schedule Of Common Stock Equivalents Were Excluded From The Calculation Of Diluted Net Loss Per Share Abstract Weighted Average Number of Shares Outstanding, Basic [Abstract] FDAApproval Of New Drug Application For Frunexian Or EP7327 Member Accrued Professional Fees, Current First Patient Dosed In Phase2 Initiated With Frunexian Or EP7327 Member Liquidity Policy Text Block Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term e XIthera APAMember Asset Acquisition Consideration Transferred In Process Research And Development Calendar Year Statement of Stockholders' Equity [Abstract] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Schedule Of Development Milestones Table Text Block Basis of Accounting, Policy [Policy Text Block] Stock Issued During Period, Value, New Issues Schedule Of Equity Based Compensation Expense Abstract Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Workings Capital Existing Warrant Shares Member Stock Issued During Period, Shares, New Issues Income Statement [Abstract] Accounting Standards Update and Change in Accounting Principle [Text Block] Other Assets, Noncurrent Operating Expenses [Abstract] Placement Agent Warrants Four Member Additional Paid in Capital Earnings Per Share, Basic Other Noncash Expense Royalty Expense Regulatory Filing Approval To Market AProduct For ASubsequent Indication In The United States Member Royalty Revenue Received Assets Liabilities Common Stock, Voting Rights Series A1 Warrants Member Research and Development Expense Subsequent Events [Text Block] Schedule Of Development Milestones Abstract Term Of Warrants Exercisable Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Location, Statement of Income, Balance [Axis] Direct Operating Costs Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Assets, Fair Value Disclosure Business Description and Accounting Policies [Text Block] Leases Commitments And Contingencies Text Block Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Schedule Of Initial Purchase Price Of The Assets Acquired Abstract Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Increase (Decrease) in Accrued Interest Receivable, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Stockholders Equity Requirement Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retained Earnings (Accumulated Deficit) Stock Issued During Period, Shares, Issued for Services Depreciation Minimum [Member] Shares, Issued Prepaid Expense and Other Assets, Current Proceeds from Stock Options Exercised Payments to Acquire Property, Plant, and Equipment Share-Based Payment Arrangement [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Accrued Employee Benefits, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Fair Value, Inputs, Level 2 [Member] Percentage Of Cash Fee Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Common Stock Outstanding Percentage Preferred Stock, Shares Outstanding Deferred Costs, Current Accounts Payable, Current Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Warrants and Rights Outstanding, Term Two Thousand Twenty Two Plan Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Increase (Decrease) in Accrued Liabilities Purchase Shares Of Common Stock Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Representative Warrants Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Maximum [Member] Income Tax, Policy [Policy Text Block] Preferred Stock, Shares Authorized Common Stock, Shares Authorized Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Subsequent Event [Member] Warrant [Member] Other Accrued Liabilities, Current Schedule of Accrued Liabilities [Table Text Block] Placement Agent Warrant One Member Share-Based Payment Arrangement, Expense Existing Warrants Member Placement Agent Warrants Two Member Lessee, Finance Lease, Term of Contract Maximum Number Of Shares Of Common Stock Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Additional Paid-in Capital [Member] Regulatory Filing Approval To Market AProduct For ASubsequent Indication Outside The United States Member Operating Income (Loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Increase (Decrease) in Prepaid Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Asset Acquisition [Table Text Block] Warrant Inducement Member Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Sale of Stock, Price Per Share Total Gross Proceeds Asset Purchase Agreement Member Interest Receivable, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term First Patient Dosed In Phase1 Initiated With EP7327 Member Stock Issued During Period, Shares, Period Increase (Decrease) Common Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accounts Payable and Accrued Liabilities Disclosure [Text Block] Common Stock, Capital Shares Reserved for Future Issuance Segment Reporting, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Class of Warrant or Right, Outstanding Statement of Cash Flows [Abstract] Royalty [Member] Fair Value, Inputs, Level 3 [Member] Stock Issued During Period Shares Stock Option Exercised New Warrants Member e XIthera Pharmaceuticals Inc Member Remained Available Shares For Future Issuance Emerging Growth Company Status Policy Text Block Fair Value, Assets Measured on Recurring Basis [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Schedule Of Assumptions Used In Black Scholes Model Abstract Liabilities, Current [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Veralox Therapeutics Inc Member Seller Royalties Percentage Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Veralox APAMember APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term Placement Agent Warrants Member Increase (Decrease) in Operating Liabilities Cash Equivalent, Money Market Fund, Carrying Value Haisco Licensing Agreement Member Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Payments Of Milestones Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Fair Value, Inputs, Level 1 [Member] Other Assets Disclosure [Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted Reserved Shares Of Common Stock Available For Issuance Earnings Per Share [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Payment Arrangement [Text Block] Revenues Cash and Cash Equivalents, Policy [Policy Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Forfeited Expired Accrued Research And Development Stock Issued During Period, Value, Issued for Services Equity, Attributable to Parent Asset Acquisition, Consideration Transferred New Series A2 Warrants Member General and Administrative Expense Asset Acquisition, Consideration Transferred, Transaction Cost Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Class Of Warrant Or Right Issue Date New Series A1 Warrants Member Increase (Decrease) in Deferred Charges Common Stock, Par or Stated Value Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Earnings Per Share, Policy [Policy Text Block] Deferred Offering Costs Policy Text Block Proceeds from Issuance of Private Placement Assets, Current Class Of Warrant Or Right Expiration Date Common Stock, Shares, Issued Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Diluted Preferred Stock, Shares Issued Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Private Placement [Member] Schedule Of Total Warrants Outstanding Abstract Operating Lease, Expense Fair Value Disclosures [Text Block] Cash, FDIC Insured Amount Series B2 Warrants Member Share-Based Payment Arrangement, Option, Activity [Table Text Block] Placement Agent Warrants Three Member Equity [Text Block] Assets, Current [Abstract] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Sale of Stock, Number of Shares Issued in Transaction Lessee, Operating Lease, Liability, to be Paid Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Statement of Financial Position [Abstract] Operating Expenses Increase (Decrease) in Accounts Payable Liabilities, Current Schedule Of Basic And Diluted Net Loss Per Common Share Abstract Cash and Cash Equivalent First USFDAApproval For Seller Patented Verilox Product Member Percentage Of Uncertain Income Tax Position Proceeds from Debt, Net of Issuance Costs Accrued Liabilities, Current Class of Warrant or Right, Exercise Price of Warrants or Rights Research and Development Expense, Policy [Policy Text Block] Lessee, Operating Lease, Liability, to be Paid, Year One Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Proceeds from Issuance of Common Stock Acquisitions Policy Text Block Shares, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Investment Income, Interest and Dividend Liabilities and Equity [Abstract] Payments for Purchase of Other Assets Number of Reportable Segments Liabilities and Equity Share-Based Payment Arrangement, Noncash Expense Percentage Of Exercise Price Of New Warrants Segment Reporting, Expense Information Used by CODM, Description Nonoperating Income (Expense) Preferred Stock, Value, Issued First Regulatory Filing Approval To Market AProduct Outside The United States Member Preferred Stock, Par or Stated Value Per Share Net Proceeds Series B1 Warrants Member